Wednesday, June 26, 2013

Imprimis Pharmaceuticals Begins Enacting Long-Term Business Strategy to obtain IP from PCCA By Staff and Wire Reports Wednesday, 26 June 2013 07:13

mprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) has taken the first steps in implementing its long-term drug development strategy. 
On June 17, 2013, Imprimis announced it has acquired rights to certain intellectual property (IP) related to certain innovations from the compounding pharmacy operations of Buderer Drug Company.  Imprimis is a specialty pharmaceutical company uniquely focused on the commercial development of compounded drug formulations, which are initially designed by compounding pharmacies.  Imprimis has one drug candidate, Impracor, a topical NSAID, for the treatment of pain from sprains, strains and joint pain.  Impracor is expected to begin Phase III trials in the 3rd quarter of 2013. 

In 2012 Imprimis entered a relationship with Professional Compounding Centers of America, Inc. (PCCA).  This relationship provides Imprimis with exclusive access to PCCA’s library of approximately 10,000 compounded drug formulations and PCCA’s database of corresponding patient and prescriber clinical experience information collected by PCCA’s service center.  Imprimis has put together a system to mine the library for potential large market drugs.  The library contains compound formulations developed by both PCCA and compound pharmacies that are part of PCCA’s over 3,900 members.  Buderer Drug Company is one of PCCA’s members. 

continue reading here

No comments: